EUVIMEDEUVIMED entdecken
Open Access

The Health Costs of Cost Sharing

Amitabh Chandra, Evan Flack, Ziad Obermeyer

The Quarterly Journal of Economics · 09.10.2024 · 139 (4) · 2037-2082

DOI: 10.1093/qje/qjae015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Quarterly Journal of Economics, online erschienen am 03.05.2024. Verfasst von Amitabh Chandra und 2 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Kennedy School, Harvard Business School, and National Bureau of Economic Research, United States. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institute on Aging.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

What happens when patients suddenly stop their medications? We study the health consequences of drug interruptions caused by large, abrupt, and arbitrary changes in price. Medicare’s prescription drug benefit as-if-randomly assigns 65-year-olds a drug budget as a function of their birth month, beyond which out-of-pocket costs suddenly increase. Those facing smaller budgets consume fewer drugs and die more: mortality increases 0.0164 percentage points per month (13.9%) for each $100 per month budget decrease (24.4%). This estimate is robust to a range of falsification checks and lies in the 97.8th percentile of 544 placebo estimates from similar populations that lack the same idiosyncratic budget policy. Several facts help make sense of this large effect. First, patients stop taking drugs that are both high value and suspected to cause life-threatening withdrawal syndromes when stopped. Second, using machine learning, we identify patients at the highest risk of drug-preventable adverse events. Contrary to the predictions of standard economic models, high-risk patients (e.g., those most likely to have a heart attack) cut back more than low-risk patients on exactly those drugs that would benefit them the most (e.g., statins). Finally, patients appear unaware of these risks. In a survey of 65-year-olds, only one-third believe that stopping their drugs for up to a month could have any serious consequences. We conclude that far from curbing waste, cost sharing is itself highly inefficient, resulting in missed opportunities to buy health at very low cost ($11,321 per life-year).

Autor:innen und Institutionen

  • Harvard Kennedy School, Harvard Business School, and National Bureau of Economic Research, United States.
  • Stanford University, United States.
  • University of California, Berkeley School of Public Health and National Bureau of Economic Research, United States.

Förderung

  • NIA NIH HHS
  • National Institute on Aging

Zitieren

APA

Chandra, A., Flack, E., & Obermeyer, Z. (2024). The Health Costs of Cost Sharing. The Quarterly Journal of Economics, 139(4), 2037-2082. https://doi.org/10.1093/qje/qjae015

Vancouver

Chandra A, Flack E, Obermeyer Z. The Health Costs of Cost Sharing. The Quarterly Journal of Economics. 2024;139(4):2037-2082. doi:10.1093/qje/qjae015

BibTeX
@article{Chandra2024,
  author = {Chandra, Amitabh and Flack, Evan and Obermeyer, Ziad},
  title = {The Health Costs of Cost Sharing},
  journal = {The Quarterly Journal of Economics},
  year = {2024},
  volume = {139},
  number = {4},
  pages = {2037--2082},
  doi = {10.1093/qje/qjae015}
}
Kostenlos starten →